276 related articles for article (PubMed ID: 26418745)
1. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Guan J; Umapathy G; Yamazaki Y; Wolfstetter G; Mendoza P; Pfeifer K; Mohammed A; Hugosson F; Zhang H; Hsu AW; Halenbeck R; Hallberg B; Palmer RH
Elife; 2015 Sep; 4():e09811. PubMed ID: 26418745
[TBL] [Abstract][Full Text] [Related]
2. Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.
Reshetnyak AV; Murray PB; Shi X; Mo ES; Mohanty J; Tome F; Bai H; Gunel M; Lax I; Schlessinger J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15862-7. PubMed ID: 26630010
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J; Wolfstetter G; Siaw J; Chand D; Hugosson F; Palmer RH; Hallberg B
Oncotarget; 2017 Feb; 8(7):11566-11578. PubMed ID: 28030793
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of cytokine-mediated activation of ALK family receptors.
De Munck S; Provost M; Kurikawa M; Omori I; Mukohyama J; Felix J; Bloch Y; Abdel-Wahab O; Bazan JF; Yoshimi A; Savvides SN
Nature; 2021 Dec; 600(7887):143-147. PubMed ID: 34646012
[TBL] [Abstract][Full Text] [Related]
5. ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells.
Fadeev A; Mendoza-Garcia P; Irion U; Guan J; Pfeifer K; Wiessner S; Serluca F; Singh AP; Nüsslein-Volhard C; Palmer RH
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E630-E638. PubMed ID: 29317532
[TBL] [Abstract][Full Text] [Related]
6. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.
Murray PB; Lax I; Reshetnyak A; Ligon GF; Lillquist JS; Natoli EJ; Shi X; Folta-Stogniew E; Gunel M; Alvarado D; Schlessinger J
Sci Signal; 2015 Jan; 8(360):ra6. PubMed ID: 25605972
[TBL] [Abstract][Full Text] [Related]
7. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
8. Multifaceted Roles of ALK Family Receptors and Augmentor Ligands in Health and Disease: A Comprehensive Review.
Katic L; Priscan A
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892172
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
Perez-Pinera P; Zhang W; Chang Y; Vega JA; Deuel TF
J Biol Chem; 2007 Sep; 282(39):28683-28690. PubMed ID: 17681947
[TBL] [Abstract][Full Text] [Related]
10. Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.
Zhang H; Pao LI; Zhou A; Brace AD; Halenbeck R; Hsu AW; Bray TL; Hestir K; Bosch E; Lee E; Wang G; Liu H; Wong BR; Kavanaugh WM; Williams LT
Proc Natl Acad Sci U S A; 2014 Nov; 111(44):15741-5. PubMed ID: 25331893
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase: "Ligand Independent Activation" mediated by the PTN/RPTPβ/ζ signaling pathway.
Deuel TF
Biochim Biophys Acta; 2013 Oct; 1834(10):2219-23. PubMed ID: 23777859
[TBL] [Abstract][Full Text] [Related]
12. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.
Moog-Lutz C; Degoutin J; Gouzi JY; Frobert Y; Brunet-de Carvalho N; Bureau J; Créminon C; Vigny M
J Biol Chem; 2005 Jul; 280(28):26039-48. PubMed ID: 15886198
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
Zhao Z; Verma V; Zhang M
Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
[TBL] [Abstract][Full Text] [Related]
14. Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.
Mo ES; Cheng Q; Reshetnyak AV; Schlessinger J; Nicoli S
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12027-12032. PubMed ID: 29078341
[TBL] [Abstract][Full Text] [Related]
15. A ligand for ALK.
Lemke G; Lew ED
Sci Signal; 2015 Jan; 8(360):fs2. PubMed ID: 25605971
[TBL] [Abstract][Full Text] [Related]
16. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
[TBL] [Abstract][Full Text] [Related]
17. Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
Fukuhara S; Nomoto J; Kim SW; Taniguchi H; Miyagi Maeshima A; Tobinai K; Kobayashi Y
Hematol Oncol; 2018 Feb; 36(1):150-158. PubMed ID: 28665006
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
Murugan AK; Xing M
Cancer Res; 2011 Jul; 71(13):4403-11. PubMed ID: 21596819
[TBL] [Abstract][Full Text] [Related]
19. Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase.
Machino M; Gong Y; Ozaki T; Suzuki Y; Watanabe E; Imagama S; Kadomatsu K; Sakamoto K
J Biochem; 2021 Dec; 170(5):631-637. PubMed ID: 34270745
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
